Gastric/Gastroesophageal Junction Cancer
5
1
1
2
Key Insights
Highlights
Success Rate
100% trial completion (above average)
Clinical Risk Assessment
Based on trial outcomes
Moderate Risk
Score: 37/100
0.0%
0 terminated out of 5 trials
100.0%
+13.5% vs benchmark
0%
0 trials in Phase 3/4
50%
1 of 2 completed with results
Key Signals
Data Visualizations
Phase Distribution
Trial Status
Trial Success Rate
Benchmark: 86.5%
Based on 2 completed trials
Clinical Trials (5)
Study to Assess the Effect of OCT-598 in Patients With Advanced Solid Tumors
A Clinical Trail of KJ015 in Patients With HER2-Expressing Solid Tumors
A Study to Investigate Sitravatinib as Monotherapy and in Combination With Tislelizumab in Participants With Unresectable Locally Advanced or Metastatic Hepatocellular Carcinoma or Gastric/Gastroesophageal Junction Cancer
KN026 in Patients With HER2 Expressing Gastric/Gastroesophageal Junction Cancer
KN026 in Patients With HER2 Expressing Breast Cancer and Gastric Cancer